u/teodor_duarte

glycaemic control first, that is the original indication

Not to be pedantic but telehealth and state board are being used interchangeably and they are not interchangeable in real life.

The injection-site soreness was genuinely awful for three weeks and then simply stopped. I know that is not useful information, but it is what happened.

Disagree. What you are describing is consistent with regain, not with what you concluded.

Titration speed is a side-effect dial far more than an efficacy dial.

Disagree but this is the good kind of wrong — it is specific enough to be checked.

Adding to this: lowest effective dose is doing more work than the comment implies.

Every time this gets posted it hits the front page and every time someone has to re-explain it.

denial reason codes matter, ask for the actual code

nope, 0.25 counts, it is just not the dose most people stay on

post A1c with units and assay date

Respectfully this is a sample of one presented as a finding.

This matches my experience almost exactly on the Ozempic pens. The titration is the whole point.

Not to be pedantic but Wegovy and food noise are being used interchangeably and they are not interchangeable in real life.

Mechanistically the bit that matters is A1c. It explains most of the early profile and a decent chunk of the outcome.

Came off after 50 weeks for financial reasons. Regained about a third over the following year. Back on now at a much lower dose.

insulin and sulfonylurea interactions are real hypo risk

Stalled for 3 weeks, changed nothing, and it started moving again on week 35.

Strongly agree. API source transparency matters.

dose-stretching experiences welcome, dose-stretching instructions are not

The tier 3 pathway in my area: 24 month wait, then 24 months for review, then approved. Total tier 3.